Related Experiment Video

Updated: Aug 19, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in

Yiwei Li1, Xin Hong, Maha Hussain

  • 1Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, 715 Hudson Webber Cancer Research Center, 110 East Warren, Detroit, MI 48201, USA.

Molecular Cancer Therapeutics
|March 16, 2005
PubMed

Insights

Docetaxel and estramustine combination therapy shows promise for prostate cancer by altering gene expression. This approach may offer new molecular targets for improved treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Docetaxel and estramustine are antimicrotubule agents with demonstrated antitumor activity in prostate cancer.
  • Combination therapy has shown improved efficacy in hormone-refractory prostate cancer, but underlying molecular mechanisms remain unclear.

Purpose of the Study:

  • To elucidate the molecular mechanisms of combined docetaxel and estramustine treatment in prostate cancer.
  • To identify gene expression changes in hormone-insensitive (PC-3) and hormone-sensitive (LNCaP) prostate cancer cells.

Main Methods:

  • Gene expression profiling using Affymetrix Human Genome U133A Array on prostate cancer cells treated with docetaxel, estramustine, or combination therapy.
  • Microarray analysis of RNA extracted at 6, 36, and 72 hours post-treatment.
  • Validation of microarray data using real-time PCR and Western blot analysis.

Main Results:

  • Combination treatment down-regulated genes involved in cell proliferation, transcription, translation, and oncogenesis.
  • Combination treatment up-regulated genes associated with apoptosis induction, cell cycle arrest, and tumor suppression.
  • Differential gene expression patterns observed between monotherapy and combination treatment, with combination therapy affecting a broader range of genes.

Conclusions:

  • Docetaxel and estramustine combination therapy significantly alters gene expression in prostate cancer cells, potentially inhibiting tumor growth.
  • Identified novel molecular targets and pathways modulated by the combination treatment.
  • Findings support further research into optimized therapeutic strategies for prostate cancer using this combination.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...